Nanoparticle Probes to Objectively Measure Pain Following Back Surgery - Abstract
Post-operative pain is poorly managed and increases risk for delayed recovery, chronic pain, opioid
dependence, and persistent disability. One barrier to effective management of acute pain is the absence of
objective measures. We propose to conduct a feasibility study for technology to objectively measure post-
operative pain. We have selected back surgery as a model given its frequency, cost, and poor outcomes.
Precise tracking of inflammation and pain markers at the surgery site may provide objective measurement of
post-operative pain. Local inflammation is necessary for normal wound healing, but the degree of inflammatory
response to injury is highly variable across patients. Inflammation from wound healing begins within hours and
abates completely within a few days after surgery, when the proliferative phase of wound healing begins.
Patient-specific immune states before surgery correlate with protracted recovery, including post-operative pain,
fatigue, and functional impairment. Immune cell intracellular signaling in response to biomarkers, such as the
cytokine Interleukin-6 (IL-6), has been shown to predict slower recovery and persistent pain following primary
hip replacement surgery for osteoarthritis. Patients who have persistent local inflammation may be
distinguishable from normal wound healing by monitoring the character and time course of local inflammation
at the surgical site. Persistent pain may be associated with higher levels and longer duration of inflammation.
We hypothesize that longitudinal objective measurements of epidural temperature and concentrations of
interleukin-6 (IL-6) and substance P (SP) will correlate with post-operative pain following back surgery. We
have developed novel microscopic magnetic nanoparticle probes that can be safely implanted in the surgical
field to allow noninvasive postoperative measurements of precise local temperature and concentrations of
these biomarkers. In Aim 1 of this project, we will adapt and optimize the magnetic spectroscopy
instrumentation for use in a rat lumbar radiculopathy model. We have already validated for in vivo
measurements of infection in a mouse peritoneal cavity. In Aim 2, we will create three grades of surgical injury:
minimal (lumbar skin incision only), moderate (L5 laminectomy), and severe (L5 laminectomy and unilateral
nerve root ligation) and compare noninvasive nanoparticle-based measurements of epidural temperature, IL-6
concentration, and SP concentration to validated, video-based automated measures of pain behavior in
animals (Aim 2a), temperature measured by a thermocouple (Aim 2b), and ELISA-based epidural
concentration of IL-6 (Aim 2c) and SP (Aim 2d), at three time points following surgery (1 day, 3 days, and 10
days post-op). Phase I proof of principle demonstration of nanoparticle-based measurements will be
considered successful for associations that show a Spearman rank correlation >0.70 and Bland-Altman
agreement +/- 20% between methods, allowing us to proceed to a preliminary human safety demonstration in
a small clinical series of lumbar laminectomy and fusion patients in Phase II, and potentially expand
measurements to include a panel of other important biomarkers. This novel technology may lead to an
inexpensive, simple, point of care measurement system for noninvasively tracking post-operative pain.